Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-07-27

FDA Approved: KAZANO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Kazano (alogliptin/metformin hydrochloride) submitted by Takeda Pharmaceuticals America, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KAZANO (alogliptin and metformin hydrochloride)

Snippet

SUPPL AP for KAZANO (ALOGLIPTIN AND METFORMIN HYDROCHLORIDE)